BNET Industries
Last Fiscal Year Sales:$12.3B
- Private
- US
Dow Jones Description
Mfr. of Pharmaceuticals, Nutritionals, Biologicals, Antibiotics & Oral Contraceptives
President, Specialty Pharmaceuticals
David A. StrunceNumber of Employees 44,000
Contact Information
500 Arcola Rd
Collegeville, Pennsylvania 19426
(610) 902-1200
Peer Companies
NAICS Code Research and Development in the Social Sciences and Humanities: 541720
Recent Events
-
Pfizer's prospects open to debate: Some analysts see strong performance in wake of merger, others...
-
$75M verdict unsealed in Prempro-cancer case
-
Pfizer to close New London R&D facility
-
Zimmerman: Who can we trust if FDA puts stamp on snake oil?
-
Pfizer leaders get $2.2 million in bonuses
-
Workers at Pfizer dig deep for United Way
-
Progenics Pharma PGNX Regains RELISTOR Rights from Wyeth WYE
-
Progenics Pharmaceuticals, Inc. PGNX Regains Rights to Relistor from Wyeth WYE JOBS; Progenics to Receive...
-
WYETH PHARMACEUTICALS INITIATES PHASE II AND PAYS ABLYNX ANOTHER MILESTONE IN THE TNF-alpha NANOBODYR COLLABORATION
-
Wyeth Adjusts To Changes From Pharmaceutical Codes Of Conduct
-
Wyeth Pharmaceuticals signs agreement with Ambrx
-
Progenics Announces Promotion of Mark R. Baker to President and
-
Ablynx Announces Half-Year Results For 2009
-
Wyeth used ghostwriters to tout hormone drugs
-
Progenics Announces Second Quarter 2009 Financial Results
-
Business in the Burbs: Towers Perrin gets IDA offer to stay in Westchester
-
WYETH PHARMACEUTICALS and CATALYST BIOSCIENCES announce agreement to develop and commercialize factor VIIa products
-
Progenics Provides Update on Hepatitis C Program
News & Analysis
Filter by
wyeth pharmaceuticals inc. - All News and Analysis
Obesity drug firm sold to US
- 2008-12-19
Business in brief PHARMACEUTICALS Imperial Innovations, the technology investment and commercialisation specialist, said yesterday that one of its portfolio companies, the obesity drug developer Thiakis, has been sold to Wyeth Pharmaceuticals for a total of 100m. Thiakis, in which Imperial has a 23.7 per cent stake, will...
Seminar in advanced rheumatology: selected proceedings of a live symposium held March, 2008 bulletin of the NYU hospital for joint diseases
- 2008-09-01
Supported by educational grants from: Amgen & Wyeth Pharmaceuticals; Bristol-Myers Squibb; Centocor, Inc.; Genentech/Biogen IDEC; Roche Laboratories Target Audience This program is intended for physicians and allied healthcare professionals in the fields of rheumatology, orthopedics and internal medicine. Statement of Need New therapies are available for...
Drug treats constipation in terminally III patients
- 2008-09-01
The U.S. Food and Drug Administration FDA has granted approval for methylnaltrexone bromide (Relistor[R], Wyeth Pharmaceuticals) to be used in the treatment of laxative-refractory opioid-induced constipation in terminally III patients. Opioids contribute to constipation by binding to the mu-opioid receptors in the gastrointestinal tract. Methylnaltrexone bromide prevents the binding action...
Wyeth Pharmaceuticals
- 2008-06-23
Wyeth Pharmaceuticals received an approvable letter from the Food and Drug Administration for a drug to treat postmenopausal osteoporosis, the company announced. The FDA requested further analysis concerning stroke and venous thrombosis for the drug, known as bazedoxifene. The FDA made similar requests when Wyeth filed a new drug...
Temsirolimus backed for advanced kidney cancer new guidelines give the drug a category 1 endorsement based on phase III trial data
- 2008-05-01
HOLLYWOOD, FLA. --Temsirolimus, approved by the Food and Drug Administration in June 2007 for the treatment of advanced kidney cancer, is endorsed as a treatment option for advanced, poor-prognosis disease in updated guidelines from the National Comprehensive Cancer Network. The addition of temsirolimus Torisel, a mammalian target of rapamycin...
FDA approves Xyntha
- 2008-03-17
Wyeth's Xyntha has been approved by the FDA for treating hemophilia A. The product, developed by Wyeth Pharmaceuticals, is said to take an innovative approach to controlling bleeding episodes.
More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms.
- 2008-03-12
MADISON, New Jersey, March 12 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it would need to conduct additional clinical studies to address questions from the Committee for Medicinal Products for Human Use CHMP regarding the risk-benefit profile...
Crucell Announces Vaccine Development Agreement with Wyeth Pharmaceuticals
- 2008-03-03
Leiden, The Netherlands, 3 March 2008 - Dutch biotechnology company Crucell N.V. today announced that it has entered into an exclusive vaccine development agreement with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE). Under the terms of the agreement, Crucell will be responsible...
Wyeth Pharmaceuticals
- 2008-01-01
Philadelphia, PA The Center for Drugs Division of Drug Marketing, Advertising, and Communications DDMAC reviewed a professional journal ad submitted by Wyeth for Effexor XR venlafaxine HCI Tablets Effexor XR and determined the ad "is misleading because it overstates the efficacy of Effexor XR, makes unsubstantiated superiority claims, in...
Wyeth Pharmaceuticals
- 2007-12-24
Joseph Mahady has been promoted to president, Wyeth Pharmaceuticals and senior vice president, Wyeth. He was previously president of global business for Wyeth Pharmaceuticals. Other promotions include Richard DeLuca, to president of veterinary medicines manufacturer and Wyeth subsidiary, Fort Dodge Animal Health. Cavan Redmond became president, Wyeth Consumer Healthcare and...
Decision Makers
| Name (plus bio) | Position |
|---|---|
| David A. Strunce | President, Specialty Pharmaceuticals |
| Joseph Mahady | President, Pharmaceuticals Division |
| Mark Larsen | President, EMEA |
| Michael Day | President, Women's Healthcare |
| Richard DeLuca | President, Animal Health Division |
| Robert Power | President, Intl |
| Emilio Emini | Executive Vice President, Vaccines Res & Development |
| Hans Mueller | Senior Vice President, Business Development |
| Hilary Malone | Senior Vice President, Global Regulatory Affairs |
| Doug Petkus | Assistant Vice President, US Communications |
| George Irwin | Vice President, Quality Assurance |
| James B. Parsons | Vice President, Business Unit Director |
| Marily Rhudy | Vice President, Public Affairs |
| Mike Marquard | Vice President, Pharmaceutical Sales |
| Charles Ulmann | Manager, Telecomm |
| Don Zembruski | Manager, Audio Visual |
| Geno Germano | Executive Vice President & General Manager, Global Vaccines |
| Adolfo L Gomez | |
| Burt Shotton | Treasurer |
| Dane Shelly | |
| Denise Peppard | Head, Human Resources |
| Lilian G Yengi |
| Organization | Position | Status |
|---|---|---|
| Wyeth Pharmaceuticals, Inc. | President, Specialty Pharmaceuticals | Current |
| Organization | Position | Status |
|---|---|---|
| Wyeth Pharmaceuticals, Inc. | President, Pharmaceuticals Division | Current |
| Wyeth | Senior Vice President | Current |
| Wyeth Pharmaceuticals, Inc. | President, Wyeth North America | Former |
| Organization | Position | Status |
|---|---|---|
| Wyeth Pharmaceuticals, Inc. | President, EMEA | Current |
| Organization | Position | Status |
|---|---|---|
| Wyeth Pharmaceuticals, Inc. | President, Women's Healthcare | Current |
| Organization | Position | Status |
|---|---|---|
| Wyeth Pharmaceuticals, Inc. | President, Animal Health Division | Current |
| Wyeth Pharmaceuticals, Inc. | Chief Operating Officer, Fort Dodge Animal Health Facility | Former |
| Organization | Position | Status |
|---|---|---|
| Wyeth Pharmaceuticals, Inc. | President, Intl | Current |
| Organization | Position | Status |
|---|---|---|
| Wyeth Pharmaceuticals, Inc. | Executive Vice President, Vaccines Res & Development | Current |
| Organization | Position | Status |
|---|---|---|
| Wyeth Pharmaceuticals, Inc. | Senior Vice President, Business Development | Current |
| Organization | Position | Status |
|---|---|---|
| Wyeth Pharmaceuticals, Inc. | Senior Vice President, Global Regulatory Affairs | Current |
| Organization | Position | Status |
|---|---|---|
| Wyeth Pharmaceuticals, Inc. | Assistant Vice President, US Communications | Current |
| Organization | Position | Status |
|---|---|---|
| Wyeth Pharmaceuticals, Inc. | Vice President, Quality Assurance | Current |
| Organization | Position | Status |
|---|---|---|
| Wyeth Pharmaceuticals, Inc. | Vice President, Business Unit Director | Current |
| Organization | Position | Status |
|---|---|---|
| Wyeth Pharmaceuticals, Inc. | Vice President, Public Affairs | Current |
| Organization | Position | Status |
|---|---|---|
| Wyeth Pharmaceuticals, Inc. | Vice President, Pharmaceutical Sales | Current |
| Organization | Position | Status |
|---|---|---|
| Wyeth Pharmaceuticals, Inc. | Manager, Telecomm | Current |
| Organization | Position | Status |
|---|---|---|
| Wyeth Pharmaceuticals, Inc. | Manager, Audio Visual | Current |
| Organization | Position | Status |
|---|---|---|
| Wyeth Pharmaceuticals, Inc. | Executive Vice President & General Manager, Global Vaccines | Current |
| Organization | Position | Status |
|---|---|---|
| More Trial, Less Error | President | Current |
| Emerson Resources, Inc. | Vice President, Scientific Affairs | Current |
| Ideas, Inc. | Principal | Current |
| American Association of Pharmaceutical Scientists | Member | Current |
| Duramed Pharmaceuticals, Inc. | Current | |
| Lederle Laboratories | Current | |
| Wyeth Pharmaceuticals, Inc. | Current | |
| Granutec | Current | |
| American Association of Pharmaceutical Scientists | Board of Directors | Current |
| Long Island University | Master of Science In Pharmaceutics | Former |
| Rutgers University | Bachelor of Science In Biochemistry | Former |
| Organization | Position | Status |
|---|---|---|
| Wyeth Pharmaceuticals, Inc. | Treasurer | Current |
| Organization | Position | Status |
|---|---|---|
| The Institute for Global Engagement | Research Assistant | Current |
| Wyeth Pharmaceuticals, Inc. | Current | |
| The Catholic University of America | Former |
| Organization | Position | Status |
|---|---|---|
| Wyeth Pharmaceuticals, Inc. | Head, Human Resources | Current |
| Wyeth | Senior Vice President - Human Resources | Current |
| Wyeth Pharmaceuticals, Inc. | Vice President, Human Resources | Former |
Lilian Yengi graduated from Keele University (UK) with a BSc (Joint Honors) in Biochemistry and Biology followed by Leeds University (UK) where she obtained a Masters degree in Clinical Biochemistry. She then continued her studies at Staffordshire University, where she pursued a Ph.D. program in Molecular Biology, with Professor RC Strange as adviser. As part of this program, she studied the influence of genetic polymorphisms o n disease susceptibility, with particular reference to cancer and inflammatory mediated diseases. She was involved in the identification of novel polymorphisms that, in combination with environmental factors, either conferred protection or increased an individual's susceptibility to certain cancers such as cervical and skin cancers. After a 2-year postgraduate fellowship with Professor Roland Wolf at the Biomedical Research Center, Dundee University (Scotland), she joined Wyeth Pharmaceuticals in 2000, where she currently works in the Drug Safety and Metabolism Department. She heads a group mandated with identifying and developing novel molecular-based technologies and applying these in an issue driven manner to support the progression of new molecular entities into the drug development track. She has several peer-reviewed publications in her field and is a member of the International Society for the Study of Xenobiotics (ISSX).
| Organization | Position | Status |
|---|---|---|
| Issx | Member | Current |
| African Society for Toxicological Sciences | Adviser | Current |
| Wyeth Pharmaceuticals, Inc. | Current | |
| African Society for Toxicological Sciences | Treasurer | Current |
| Leeds University | Masters Degree In Clinical Biochemistry. | Former |
Executive News
-
Norwich Pharmaceuticals Announces Alliance with Emerson Resources
-
Norwich Pharmaceuticals Announces Alliance with Emerson Resources
Industry Transcripts by Seeking Alpha
-
51jobs Q3 2009 Earnings Call Transcript
on Nov 23, 2009about JOBS
-
NetEase Q3 2009 Earnings Call Transcript
on Nov 18, 2009about NTES
-
Franklin Covey Co. F4Q09 (Qtr End 08/31/09) Earnings Call Transcript
on Nov 16, 2009about FC
-
Cellcom Israel Ltd. Q3 2009 Earnings Call Transcript
on Nov 16, 2009about CEL
-
URS Corporation Q3 2009 Earnings Call Transcript
on Nov 13, 2009about URS
IndustryTop Rated
